NU
ACTU

Northwestern University’s Actuate Therapeutics ACTU Stock Holding History

Northwestern University’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,488
Closed -$43.4K – 4
2025
Q3 		$43.4K Sell
6,488
-21,290
-77% -$154K 0.08% 3
2025
Q2 		$170K Hold
27,778
– – 0.3% 3
2025
Q1 		$188K Hold
27,778
– – 0.3% 4
2024
Q4 		$221K Hold
27,778
– – 0.35% 4
2024
Q3 		$207K Buy
+27,778
New +$220K 0.24% 5

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northwestern University's ACTU Position: Q4 2025 in Review

Northwestern University sold out of Actuate Therapeutics (ACTU) in Q4 2025, closing a stake of 6,488 shares — an estimated $43.4K sold.

Northwestern University first reported a position in ACTU in Q3 2024 and held it in 5 quarters. The position peaked at $221K in Q4 2024. 45 funds tracked by Wall St. Rank hold ACTU as of Q4 2025.

  • Northwestern University reported no remaining Actuate Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Northwestern University sold 6,488 Actuate Therapeutics shares in Q4 2025, an estimated $43.4K.
  • Northwestern University first reported a position in Actuate Therapeutics in Q3 2024 and held it in 5 quarters.
  • Northwestern University's Actuate Therapeutics position peaked at $221K in Q4 2024.
  • 45 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q4 2025.

Based on Northwestern University's 13F filing for Q4 2025, filed 26 Jan 2026.